Review Article

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review

Taisa Rocha Navasconi Berbert, Tatiane França Perles de Mello, Priscila Wolf Nassif, Camila Alves Mota, Aline Verzignassi Silveira, Giovana Chiqueto Duarte, Izabel Galhardo Demarchi, Sandra Mara Alessi Aristides, Maria Valdrinez Campana Lonardoni, Jorge Juarez Vieira Teixeira, and Thais Gomes Verziganassi Silveira

1Graduate Program in Health Sciences, State University Maringá, Avenida Colombo, 5790 Jardim Universitário, 87020-900, Maringá, PR, Brazil
2Graduate Program in Bioscience and Physiopathology, State University Maringá, Avenida Colombo, 5790 Jardim Universitário, 87020-900 Maringá, PR, Brazil
3Medical Residency, Santa Casa de São Paulo, R. Dr. Cesário Mota Júnior, 112 Vila Buarque, 01221-900 São Paulo, SP, Brazil
4Undergraduation Course in Medicine, State University Maringa, Avenida Colombo, 5790 Jardim Universitário, 87020-900 Maringá, PR, Brazil
5Department of Clinical Analysis and Biomedicine, State University Maringa, Avenida Colombo, 5790 Jardim Universitário, 87020-900 Maringá, PR, Brazil

Correspondence should be addressed to Thaís Gomes Verziganassi Silveira; tgvsilveira@uem.br

Received 31 August 2018; Revised 19 November 2018; Accepted 5 December 2018; Published 24 December 2018

Academic Editor: Markus Stucker

Copyright © 2018 Taisa Rocha Navasconi Berbert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The first choice drugs for the treatment of cutaneous and mucocutaneous leishmaniasis are pentavalent antimonials, sodium stibogluconate, or meglumine antimoniate. However, the treatment with these drugs is expensive, can cause serious adverse effects, and is not always effective. The combination of two drugs by different routes or the combination of an alternative therapy with systemic therapy can increase the efficacy and decrease the collateral effects caused by the reference drugs. In this systematic review we investigated publications that described a combination of nonconventional treatment for cutaneous and mucocutaneous with pentavalent antimonials. A literature review was performed in the databases Web of Knowledge and PubMed in the period from 01st of December 2004 to 01st of June 2017, according to Prisma statement. Only clinical trials involving the treatment for cutaneous or mucocutaneous leishmaniasis, in English, and with available abstract were added. Other types of publications, such as reviews, case reports, comments to the editor, letters, interviews, guidelines, and errata, were excluded. Sixteen articles were selected and the pentavalent antimonials were administered in combination with pentoxifylline, granulocyte macrophage colony-stimulating factor, imiquimod, intralesional sodium stibogluconate, ketoconazole, silver-containing polyester dressing, lyophilized LEISH-F1 protein, cryotherapy, topical honey, and omeprazole. In general, the combined therapy resulted in high rates of clinical cure and when relapse or recurrence was reported, it was higher in the groups treated with pentavalent antimonials alone. The majority of the articles included in this review showed that cure rate ranged from 70 to 100% in patients treated with the combinations. Serious adverse effects were not observed in patients treated with drugs combination. The combination of other drugs or treatment modalities with pentavalent antimonials has proved to be effective for cutaneous and mucocutaneous leishmaniasis and for most seemed to be safe. However, new randomized, controlled, and multicentric clinical trials with more robust samples should be performed, especially the combination with immunomodulators.
1. Introduction

Leishmaniasis is an important zoonosis around the world, being reported that about 20,000 to 30,000 deaths occur annually as a consequence of the disease [1]. The most frequent form is cutaneous leishmaniasis (CL), which is present in several countries, mainly in the Americas, the Mediterranean basin, the Middle East, and Central Asia. An annual occurrence of 0.6 to 1.0 million new cases is estimated [2] and around 399 million of people are at risk of infection in 11 high-burden countries [1].

The pentavalent antimonials, sodium stibogluconate or meglumine antimoniate, are drugs commonly used to treat cutaneous and mucocutaneous leishmaniasis. However, the treatment with these drugs is expensive and can cause serious adverse effects, such as cardiac toxicity and elevation in the levels of hepatic enzymes [3–5], and, sometimes, it is ineffective or presents low cure rates [6, 7]. Amphotericin B, pentamidine, fluconazole, and miltefosine can be used as second choice drugs, but they also exhibit toxicity. Moreover, the efficacy of the treatment also depends on the Leishmania species involved in the infection, since some species are more resistant to some drugs [6].

Local therapies, such as cryotherapy, CO₂ laser, thermal therapy, and photodynamic therapy, are alternatives to conventional drugs, since they are less toxic to the patient and the main adverse effects are restricted to the site of application [8–13]. However, the exclusive use of local therapy is controversial, since some New World species can lead to mucosal leishmaniasis after primarily cutaneous lesions [3].

The combination of two drugs or the combination of a local therapy with systemic therapy can be an alternative to increase the efficacy of local therapy and may decrease the collateral effects caused by the reference drugs. Some studies have evaluated the efficacy of this type of combination [14–17], being necessary prospective and multicenter studies for safer evidence. Our central question was evaluated if the combination of an alternative therapy with pentavalent antimonials for cutaneous or mucocutaneous leishmaniasis was included in this review. Only original clinical trials, in English and with abstract available, were added. Other types of publications (reviews, case reports, comments to the editor, letters, interviews, guidelines, and errata) were excluded. After the search the papers initially selected were analyzed by the researchers of group 1 (TRNB, CAM, PWN, TFPMP, GCD, and AVS) and disagreements about inclusion or exclusion of articles were decided by consensus. To increase the search sensitivity, the researchers in group 1 checked all references from the selected publications to retrieve other unidentified publications in the other phases of the search. The validation of selected articles was performed by four independent evaluators of group 2 (TGVS, MVCL, SMAA, and IGDS).

2. Methodology

2.1. Literature Search. A literature review was performed in the databases Web of Knowledge and PubMed, considering the period from 01st December 2004 to 01st June 2017 according to Prisma statement [18]. The screening of the titles and abstracts was performed by researchers (TRNB, CAM, PWN, TFPMP, GCD and AVS). The MeSH (Medical Subject Headings) terms, strategy used for the search on PubMed, were also selected by these researchers based on publications on the topic at PubMed. Any disagreements were decided by consensus. The MeSH terms were validated by two experts (JVT and TGVS) and were divided into two groups: Group 1 “Antiprotozoal Agents” OR “Combined Modality Therapy” OR “Drug Therapy, Combination” OR “Treatment Outcome” OR “Amphotericin B” OR “Meglumine” OR “Protozoan Drugs” OR “Organometallic Compounds” OR “Antimony Sodium Gluconate” OR “Antimony” OR “Pentamidine” OR “Anti-Infective Agents” OR “Medication Therapy Management” OR “Complementary Therapies”; AND Group 2 “Leishmaniasis” OR “Leishmania”. The research in the Web of Knowledge database was carried out by topic, which ensures good sensitivity.

2.2. Inclusion, Exclusion Criteria, and Studies Selection. Articles that describe a combination of therapeutic alternatives with pentavalent antimonials for cutaneous or mucocutaneous leishmaniasis were included in this review. Only original clinical trials, in English and with abstract available, were added. Other types of publications (reviews, case reports, comments to the editor, letters, interviews, guidelines, and errata) were excluded. After the search the papers initially selected were analyzed by the researchers of group 1 (TRNB, CAM, PWN, TFPMP, GCD, and AVS) and disagreements about inclusion or exclusion of articles were decided by consensus. To increase the search sensitivity, the researchers in group 1 checked all references from the selected publications to retrieve other unidentified publications in the other phases of the search. The validation of selected articles was performed by four independent evaluators of group 2 (TGVS, MVCL, SMAA, and IGDS).

2.3. Data Extraction. The structure of the topics to compose the tables was organized by researchers from group 1 with the support of two experts (TGVS and JVT): Table 1 (study, area country, study design, period of study, age range or mean in years, gender, clinical forms, patients enrolled, leishmaniasis diagnosis, and statistics); Table 2 (study, Leishmania species, treatment, patients at the end, percentage of clinically healed patients or lesions, percentage of therapy failure, and percentage of relapse or recurrence); Table 3 (treatment, side effects percentage, and study source); and Table 4 (treatment, dose, route of administration, time efficacy, safety, practice/clinical implications, and study source). The tables were completed by researchers in group 1 and then checked by researchers from group 2.

3. Results

Based on the inclusion criteria defined by consensus, 16 articles were selected, being from Iran (6), Peru (4), Brazil (4), Yemen (1), and Afghanistan (1) (see Figure 1). In all, 1,302 patients aged between 1 and 87 years were involved in the studies, with cutaneous or mucocutaneous leishmaniasis, being predominant the cutaneous form of the disease. The most reported species of Leishmania were L. braziliensis, L. tropica, and L. major (Table 1).

In the selected articles, pentavalent antimonials were administered in combination with different drugs or treatment modalities, which were pentoxifylline; granulocyte macrophage colony-stimulating factor; imiquimod; intralesional sodium stibogluconate; ketoconazole; nonsilver-containing...
| Study source             | Area, Country | Study design                      | Period of study | Age range, mean (years) | Gender               | Clinical form | Patients enrolled | Leishmania diagnosis                                                                 | Statistics |
|-------------------------|---------------|-----------------------------------|----------------|------------------------|----------------------|---------------|------------------|-------------------------------------------------------------------------------------|------------|
| Almeida et al., 2005    | Bahia, Brazil | Open-label clinical trial         | NR             | 14-25, 18              | Male 60% Female 40%  | Cutaneous     | 5                | Clinical and Laboratory (skin test, and isolation in culture)                       | No         |
| Arevalo et al., 2007    | Lima, Peru    | Comparative study; Randomized Controlled Trial | 8/2005–10/2005 | 18-87, 34.9           | Male 55% Female 45%  | Cutaneous     | 20               | Clinical and Laboratory (microscopy, culture, and/or PCR, and Montenegro skin test) | Yes        |
| Brito et al., 2017      | Bahia, Brazil | Randomized controlled trial       | 12/2010–10/2013 | 18-62                 | Predominance of male | Cutaneous     | 162              | Clinical and laboratorial (Leishmania skin test, and/or histopathology, culture and PCR) | Yes        |
| El-Sayed & Anwar, 2010  | Sanaa, Yemen  | Comparative study; Randomized Controlled Trial | 6/2006–6/2007 | 12-50, 23.5           | Male 53.3% Female 46.7% | Cutaneous     | 30               | Clinical and Laboratory (smear for amastigote and tissue culture)                   | Yes        |
| Farajzafeh et al., 2015 | Iran          | Randomized clinical trial         | 2011-2012      | 2-60, 18.52            | Male 34 Female 36 NR 10 | Cutaneous     | 80               | Laboratory (smear microscopy)                                                     | Yes        |
| Firooz et al., 2006     | Razavi, Iran  | Multicenter Study; Randomized Controlled Trial | 8/2004–2005    | 12-60, 270            | Male 44.5% Female 55.5% | Cutaneous     | 119              | Laboratory (smear or culture)                                                     | Yes        |
| Khatami et al., 2013    | Kashan, Iran  | Randomized Controlled Clinical Trial | 9/200-4/2010   | 12-60, 28.8           | Male 47% Female 53%  | Cutaneous     | 83               | Laboratory (smear or culture)                                                     | Yes        |
| Llanos Cuentas et al., 2010 | Cusco, Peru | Randomized Controlled Trial       | 8/2004 – 6/2005 | 18-59                 | Male 96% Female 4%   | Mucosal       | 48               | Laboratory (microscopy, PCR or in vitro culture)                                   | Yes        |
| Machado et al., 2007    | Bahia, Brazil | Randomized Controlled Trial       | NR             | 18-65                 | Male 83% Female 17%  | Mucosal       | 23               | Laboratory (Intradermal skin test, parasite isolation by culture, and/or histopathological) | Yes        |
| Meymandi et al., 2011   | Kerman, Iran  | Comparative Study; Randomized Controlled Trial | 11/2007-8/2009 | 7-60                  | Male 46.6% Female 53.4% | Cutaneous     | 191              | Laboratory (smear or skin biopsy)                                                  | Yes        |
| Miranda-Verastegui et al., 2005 | Lima, Peru | Randomized Controlled Trial       | 2/2001 – 8/2002 | 1-78                  | Male 57.5% Female 42.5% | Cutaneous     | 40               | Laboratory (aspiration, smear, biopsy, culture, and/or PCR)                         | Yes        |
| Study source | Area, Country          | Study design                          | Period of study | Age range, mean (years) | Gender          | Clinical form | Patients enrolled | Leishmaniasis diagnosis                                      | Statistics |
|--------------|------------------------|---------------------------------------|-----------------|------------------------|-----------------|---------------|------------------|-------------------------------------------------------------|------------|
| Miranda-Verastegui et al., 2009 | Lima and Cusco, Peru | Comparative Study; Randomized Controlled Trial | 12/2005-6/2006 | 4-52                   | Male 77.5% Female 22.5% | Cutaneous      | 80               | Laboratory (smear microscopy, culture or PCR)                | Yes        |
| Nascimento et al., 2010 | Minas Gerais, Brazil   | Randomized Controlled Trial           | 10/2004-10/2006 | 18-59, 26.4            | Male 63.6% Female 36.4% | Cutaneous      | 44               | Laboratory (microscopy identification in biopsied tissue)    | Yes        |
| Nilforoushzadeh et al., 2007 | Isfahan, Iran          | Randomized Controlled Trial           | NR              | 7-70                   | Male 67.7% Female 32.3% | Cutaneous      | 90               | Laboratory (smear microscopy)                               | Yes        |
| Nilforoushzadeh et al., 2008 | Tehran, Iran           | Comparative Study; Randomized Controlled Trial | NR              | 7-70                   | Male 71.0% Female 29.0% | Cutaneous      | 124              | Laboratory (smear microscopy)                               | Yes        |
| Van Thiel et al., 2010 | Northern Afghanistan,  | Clinical Trial                        | 6/2005-11/2005  | NR                     | Dutch Troops     | Cutaneous      | 163              | Laboratory (smear microscopy, culture, and PCR)              | Yes        |

NR, not reported; PCR, polymerase chain reaction.
Table 2: Clinic, therapeutic, and epidemiological characteristics of clinical trials included in the study.

| Study source          | Leishmania species | Treatment                  | Patients at the end | Previous treatment | Clinically healed                  | Therapy failed                  | Relapse or Recurrence |
|-----------------------|--------------------|----------------------------|---------------------|--------------------|------------------------------------|---------------------------------|-----------------------|
| Almeida et al., 2005  | *L. braziliensis*   | G1 (MA + GM-CSF)          | 5                   | Yes                | 100% (before 120 days AS)          | 0% (12 months AH)              | 0% (12 months AH)      |
|                       |                    | G1 (IM)                   | 6                   | No                 | 0%                                 | 67% (20 days AS)                | 33% (3 months AS)      |
| Arevalo et al., 2007  | *Leishmania* spp.  | G2 (MA)                   | 7                   | No                 | 57% (3 months AS)                  | 43% (3 months AS)               | 0% (3 months AS)       |
|                       |                    | G3 (MA + IM)              | 7                   | No                 | 100% (3 months AS)                 | 0% (3 months AS)               | 0% (3 months AS)       |
| Brito et al., 2017    | *L. braziliensis*   | G1 (MA + PE)              | 82                  | NR                 | 45% (6 months AE)                 | 55% (6 months AE)              | NR                    |
|                       | (62% of cases)     | G2 (MA + placebo)         | 82                  | NR                 | 43% (6 months AE)                 | 57% (6 months AE)              | NR                    |
| El-Sayed & Anwar, 2010| NR                 | G1 (ilSSG)                | 10 (12 lesions)     | No                 | 50%/58.3% (12 weeks AS; patients/lesions) | 50%/41.7% (12 weeks AS; patients/lesions) | NR   |
|                       |                    | G2 (ilSSG + imSSG)        | 10 (15 lesions)     | No                 | 90%/93.3% (12 weeks AS; patients/lesions) | 10%/6.7% (12 weeks AS; patients/lesions) | NR   |
|                       |                    | G3 (ilSSG + KE)           | 10 (13 lesions)     | No                 | 90%/92.3% (12 weeks AS; patients/lesions) | 10%/77% (12 weeks AS; patients/lesions) | NR   |
| Farajzadeh et al., 2015| NR                 | G1 (Terbinafine + cryotherapy) | 40 | No (within the past 90 days) | 37.5% complete (28 days AS) | 10 partial cure<sup>2</sup> | 15 (28 days AS) | NR |
|                       |                    | G2 (MA + cryotherapy)     | 40                  | No                 | 52.5% (21 days AS)                | 7 partial cure<sup>2</sup>      | 12 (21 days AS)        | NR |
| Firooz et al., 2006 **| *L. tropica*       | G1 (MA + IM)              | 42                  | No                 | 18.6% (4 weeks AS)                | 44.1% (8 weeks AS)             | 49.2% (20 weeks AS)   | 3.1% (16 weeks AS) |
|                       |                    | G2 (MA + placebo)         | 47                  | No                 | 50.8% (20 weeks AS)               | 30.0% (4 weeks AS)              | 46.7% (20 weeks AS)   | 8.1% (16 weeks AS) |
| Khatami et al., 2013  | *L. major*         | G1 (il MA)                | 23 (40 lesions)     | No                 | 12.5% (6 weeks AS) lesions        | 65.0% (6 weeks AS)             | 65.0% (6 weeks AS)     | 0% (5 months AE)     |
|                       |                    | G2 (il MA + non-silver PD)| 21 (46 lesions)     | No                 | 40.0% (10 weeks AS) lesions       | 42.5% (10 weeks AS)            | 42.5% (10 weeks AS)    | 0% (5 months AE)     |
|                       |                    | G3 (il MA + silver PD)    | 29 (55 lesions)     | No                 | 6.5% (6 weeks AS) lesions         | 12.7 (6 weeks AS) lesions      | 6.5% (6 weeks AS)      | 36.4 (10 weeks AS) lesions  |
|                       |                    |                            |                     |                    | 6.2% (10 weeks AS) lesions        | 12.7 (6 weeks AS) lesions      | 6.2% (10 weeks AS)    | 36.4 (10 weeks AS) lesions  |
|                       |                    |                            |                     |                    | 12.7 (6 weeks AS) lesions         | 12.7 (6 weeks AS) lesions      | 74.6% (6 weeks AS)     | 49.1% (10 weeks AS) |
|                       |                    |                            |                     |                    | 74.6% (6 weeks AS) lesions        | 49.1% (10 weeks AS)            | 74.6% (6 weeks AS)     | 3.4% (5 months AE)     |
| Study source | *Leishmania* species | Treatment                  | Patients at the end | Previous treatment | Clinically healed | Therapy failed | Relapse or Recurrence |
|--------------|----------------------|----------------------------|---------------------|--------------------|------------------|----------------|----------------------|
| Llanos Cuestas et al., 2010 | *L. braziliensis*       | G1 (SSG + placebo)       | 12                  | No (within the past 30 days); 22.0% had received previously | 50% (84 days AS) | 25% (168 days AS) | 8% (336 days AS) |
|               |                      | G2 (SSG + (LEISH-F1 5 µg = 11 + MPL - SE)) |                     |                    |                  |                |                      |
|               |                      |                            |                     |                    | 50% (84 days AS) | 94% (336 days AS) |                      |
|               |                      |                            |                     |                    | Follow-up: 336 days AS |                |                      |
| Machado et al., 2007       | *L. braziliensis*       | G1 (MA + placebo)        | 12                  | No*                | 41.6% (90 days AS) | 42% (150 days AS) | 0% (2 years AE) |
|               |                      | G2 (MA + PE)              | 11                  | No*                | 82% (90 days AS)  | 0% (150 days AS) | 0% (2 years AE) |
| Meymandi et al., 2011      | *L. tropica*           | G1 (CO₂ laser)            | 80                  | No                 | 36.8% (2 weeks AS) | NR              | NR                  |
|               |                      |                            |                     |                    | 67.6% (6 weeks AS) |                |                      |
|               |                      |                            |                     |                    | 44.4% (12 weeks AS) |                |                      |
|               |                      |                            |                     |                    | 93.7% (89/95 lesions) |               |                      |
|               |                      | G2 (il MA + cryotherapy)  | 80                  | No                 | 15.8% (2 week AS) | NR              | NR                  |
|               |                      |                            |                     |                    | 57.5% (6 week AS)  |                |                      |
|               |                      |                            |                     |                    | 38.2% (12 week AS) |                |                      |
|               |                      |                            |                     |                    | 78% (74/95 lesions) |                |                      |
| Miranda-Verastegui et al., 2005 | *L. peruviana*  
*L. braziliensis* | G1 (MA + IM) 18 (35 lesions) | Yes                |                     | 6% (20 days AE)  | 278% (12 months AE) | NR                  |
|               |                      |                            |                     |                    | 50% (1 month AE)  |                |                      |
|               |                      |                            |                     |                    | 61% (2 months AE)  |                |                      |
|               |                      |                            |                     |                    | 72% (3 months AE)  |                |                      |
|               |                      |                            |                     |                    | 72% (6 months AE)  |                |                      |
|               |                      |                            |                     |                    | 72% (12 months AE) |                |                      |
|               |                      |                            |                     |                    | Follow-up: 12 months AE |               |                      |
|               |                      | G2 (MA + Vehicle) 20 (40 lesions) | Yes             |                     | 35% (3 months AE)  | 25% (12 months AE) | NR                  |
|               |                      |                            |                     |                    | 50% (6 months AE)  |                |                      |
|               |                      |                            |                     |                    | 75% (12 months AE) |                |                      |
|               |                      |                            |                     |                    | Follow-up: 12 months AE |               |                      |
Table 2: Continued.

| Study source                        | Leishmania species | Treatment                                                                 | Patients at the end | Previous treatment | Clinically healed                        | Therapy failed             | Relapse or Recurrence |
|-------------------------------------|--------------------|---------------------------------------------------------------------------|---------------------|--------------------|------------------------------------------|----------------------------|------------------------|
| Miranda-Verastegui et al., 2009     | L. peruviana, L. guyanensis, L. braziliensis | G1 (SSG + vehicle cream)                                                   | 36                  | No                 | 17.5% (20 days AS) 33% (1 month AS) 60% (3 months AS) 63% (6 months AS) 58% (9 months AS) 53% (12 months AS) Follow-up: 12 months AS 5% (20 days AS) 43% (1 month AS) 60% (2 months AS) 78% (3 months AS) 75% (6 months AS) 75% (9 months AS) 75% (12 months AS) Follow-up: 12 months AS | 41.7% (12 months AS) | NR                     |
|                                     |                    | G2 (SSG + IM)                                                             | 39                  | No                 | 5% (20 days AS) 43% (1 month AS) 60% (2 months AS) 78% (3 months AS) 75% (6 months AS) 75% (9 months AS) 75% (12 months AS) Follow-up: 12 months AS | 23.1% (12 months AS) | NR                     |
| Nascimento et al., 2010             | Leishmania spp.    | G1 (MA + (LEISH-F1 + MPL-SE))                                             | LEISH-F1 5μg = 9    | No                 | 80% (84 days AS) Follow-up: 336 days AS | 24% (84 days AS) 4% (84 days AS) |                       |
|                                     |                    |                                                                         | LEISH-F1 10μg = 8   |                    |                                          |                            |                        |
|                                     |                    |                                                                         | LEISH-F1 20μg = 8   |                    |                                          |                            |                        |
|                                     |                    | G2 (MA +MPL-SE)                                                          | 8                   | No                 | 50% (84 days AS) Follow-up: 336 days AS | 50% (84 days AS) | NR                     |
|                                     |                    |                                                                         | G3 (MA +Saline)     | 8                   | 38% (84 days AS) Follow-up: 336 days AS | 62% (84 days AS) 38% (84 days AS) |                       |
| Nilforoushzadeh et al., 2007        | Leishmania spp.    | G1 (ilMA + topical honey)                                                 | 33                  | No                 | 51.1% (6 weeks AS) Follow-up: 4 months AS | 48.9% (6 weeks AS) | NR                     |
|                                     |                    |                                                                         | G2 (il MA)          | 35                  | 71.1% (6 weeks AS) Follow-up: 4 months AS | 28.9% (6 weeks AS) | NR                     |
| Nilforoushzadeh et al., 2008        | L. tropica, L. major| G1 (MA 60 mg/kg/day + placebo)                                             | 43                  | No                 | 93% (12 weeks AS) Follow-up: 12 weeks AS | 7% (12 weeks AS) | NR                     |
|                                     |                    |                                                                         | G2 (MA 30 mg/kg/day + OM) | 36                  | 89% (12 weeks AS) Follow-up: 12 weeks AS | 11% (12 weeks AS) NR |                       |
|                                     |                    |                                                                         | G3 (MA 30 mg/kg/day + placebo) | 45                  | 80% (12 weeks AS) Follow-up: 12 weeks AS | 20% (12 weeks AS) |                       |
| Van Thiel et al., 2010              | L. major           | G1 (il SSG)                                                               | 118                 | No                 | 55.1% (6 months AE) Follow-up: 6 months AE | 20.3% (6 months AE) 15.3% (6 months AE) |                       |
|                                     |                    |                                                                         | G2 (il SSG + cryotherapy) | 45                  | 66.7% (6 months AE) Follow-up: 6 months AE | 13.3% (6 months AE) 11.1% (6 months AE) |                       |

NR, not reported; G1, Group 1; G2, Group 2; G3, Group 3.
MA, meglumine antimoniate; PE, pentoxifylline; GM-CSF, granulocyte macrophase colony-stimulating factor; IM, imiquimod; il SSG, intraleisional sodium stibogluconate; im SSG, intramuscular sodium stibogluconate; KE, ketoconazole; il MA (intraleional meglumine antimoniate); non-silver PD, non-silver containing polyester dressing; silver PD, silver containing polyester dressing; SSG, sodium stibogluconate; LEISH-F1, lyophilized LEISH-F1 protein; MPL-SE, adjuvant; OM, omeprazole.

AS after the start of treatment, AE: after the end of treatment, and AH: after the healing of the lesion.

*No previous treatment of mucosal leishmaniasis. Some patients had previous cutaneous leishmaniasis, but there are no references to previous treatment or not.

**Clinical cure rate, therapy failure, and relapse or recurrence given by Firooz et al., 2006, based on the initial number of patients allocated in each group.

Partial cure Farajzadeh: decrease in induration size between 25 and 75%.
Table 3: Description of adverse effects of combinations for the treatment of tegumentary leishmaniasis.

| Treatment                               | Side effects                                                                 | Study source                      |
|-----------------------------------------|-----------------------------------------------------------------------------|-----------------------------------|
| MA + IM                                 | Localized pruritus, erythema and edema (77%); arthralgia, myalgia, flu-like symptoms (86%); and elevated liver enzyme levels (64%). | Arevalo et al., 2007              |
|                                         | Moderate pruritus and burning sensation (71%).                              | Firooz et al., 2006               |
|                                         | Edema (35%); itching (10%); burning (15%); pain (5%); erythema (55%).        | Miranda-Verastegui et al., 2005   |
| MA + PE                                 | Nausea (27.3%); arthralgias (9.1%); dizziness, abdominal pain, and diarrhea (9.1%). | Machado et al., 2007              |
|                                         | Vomiting (2.4%); Diarrhea (1.2%); Nausea (8.6%); Headache (11%); Asthenia (3.7%); Anorexia (3.7%); Epigastralgia (3.7%); Pain (2.4%); Dizziness (2.4%); Fever (7.4%); Arthralgia (8.6%); Myalgia (13.5%) | Brito et al., 2017                |
| MA + cryotherapy                        | No adverse effects were observed                                            | Farajzadeh et al., 2015           |
| MA + (LEISH-F1 + MPL-SE)                | Local: induration (44.4 – 77.8%); erythema (11.1 – 100%); tenderness (33.3–44.4%). Systemic: headache (0–22.2%); pyrexia (0–22.2%); MA-related AEs (22.2 – 88.9%). | Nascimento et al., 2010           |
| MA + GM-CSF                             | No adverse effects were observed                                            | Almeida et al., 2005              |
| MA + OM                                 | NR                                                                          | Nilforoushzadeh et al., 2008      |
| il MA + silver PD                       | Itching and burning (35.3%); edema (33.3%).                                 | Khatami et al., 2013              |
| il MA + topical honey                    | Dermatitis to honey (3%).                                                   | Nilforoushzadeh et al., 2007      |
| il MA + cryotherapy                     | Hyper pigmentation+trivial scar (18.7%); atrophic scar (75%); hypopigmentation+trivial scar (18.8%). | Meymandi et al., 2011             |
| SSG + (LEISH-F1 + MPL-SE)               | Local: induration (41.7 – 75.0%); erythema (50.0 – 100.0%); tenderness (66.7 – 91.7%). Systemic: anorexia (0 – 8.3%); fatigue (0 – 8.3%); malaise (25.0%); myalgia (0 – 8.3%); headache (33.3 – 50.0%). SSG-related (100%). | Llanos Cuentas et al., 2010       |
| SSG + IM                                | Swelling (30%); itching (25%); pain (12.5%); erythema (32.5%).               | Miranda-Verastegui et al., 2009    |
| il SSG + im SSG                         | im SSG: Pain at the injection site (100%).                                   | El-Sayed & Anwar, 2010            |
| il SSG + KE                             | KE: No.                                                                     | El-Sayed & Anwar, 2010            |
| il SSG + cryotherapy                    | Secondary infection (31%); lymphatic involvement (48.8%); pain at the injection site | Van Thiel et al., 2010            |

NR, not reported; GI, Group I; G2, Group 2; G3, Group 3. MA, meglumine antimoniate; PE, pentoxifylline; GM-CSF, granulocyte macrophage colony-stimulating factor; IM, imiquimod; il SSG, intralesional sodium stibugluconate; im SSG, intramuscular sodium stibugluconate; KE, ketoconazole; il MA (intralesional meglumine antimoniate); non-silver PD, non-silver containing polyester dressing; silver PD, silver containing polyester dressing; SSG, sodium stibogluconate; LEISH-F1, lyophilized LEISH-F1 protein; MPL-SE, adjuvant; OM, omeprazole; AEs, adverse events.

Among the patients involved in the studies, 92.0% (1199/1302) ended the treatment, of which 48.0% (575/1199) underwent a combination treatment (antimonial pentavalent plus other treatment) and the remaining 52.0% (624/1199) were treated only with pentavalent antimonials or other treatment modalities (Table 2). Most of them had not undergone previous treatments.

The combination of drugs revealed high rates of clinical cure among the groups treated with drug combination. Two papers reported a cure rate of 100% in these groups (Almeida et al. 2005 [19]; Arevalo et al. 2007 [20]), while 8 authors reported 70-94% cure in the groups treated with combinations (El-Sayed and Anwar 2010 [21]; Llanos Cuentas et al. 2010 [22]; Machado et al. 2007 [15]; Meymand et al. 2011 [10]; Miranda-Verastegui et al. 2005 [23]; Miranda-Verastegui et al. 2009 [24]; Nascimento et al. 2010 [25]; Nilforoushzadeh et al. 2008 [26]). The other authors reported cure rates below 70% and ranged from 36.4% to 66.7%. The lowest cure rate was (36.4%) in the combination of IL-MA+ silver PD (Khatami et al. 2013 [27]) (Table 2).

Among the combinations, those with 100% of cure rate were meglumine antimoniate (MA) plus granulocyte macrophage colony-stimulating factor (GM-CSF) (Almeida et al. 2010) and meglumine antimoniate plus imiquimod (Arevalo et al. 2007). The other combinations that resulted in 70-94% of cure were the combinations of sodium stibogluconate (SSG) plus LEISH-F1 + MPL-SE (94%) (Llanos...
Table 4: Conclusion on combination treatment as a new treatment of tegumentary leishmaniasis in the systematic review.

| Treatment                      | Dose                                                      | Route of Administration/Time | Time   | Efficacy     | Safety                      | Practice/clinical implications     | Study source       |
|--------------------------------|-----------------------------------------------------------|-------------------------------|--------|--------------|-----------------------------|------------------------------------|-------------------|
| MA + IM                        | IM: Lesion ≤3 cm: 1 dose of 7.5% cream. Lesion > 3 cm: 2 doses of 7.5% cream. Each dose = 125 mg. MA: 20 mg/kg/day. IM: 5% cream. MA: 20 mg Sb<sup>5+</sup>/kg/day. IM: 5% cream. MA: 20 mg/kg/day. | IM: topical - daily           | 20 days| Efficacious  | Acceptable risk with specialized monitoring | Investigational | Arevalo et al., 2007 |
| MA + PE                        | MA: 20 mg<sup>5+</sup>/kg/day MA: 400 mg PE: 20 mg<sup>5+</sup>/kg/day PE: 400 m | MA: daily PE: oral - 3 times daily MA: IV - daily PE: oral - 3 times daily | MA: 30 days PE: 30 days MA: 20 days PE: 20 days | Efficacious | Acceptable risk with specialized monitoring | Clinically useful | Machado et al., 2007 |
| MA + cryotherapy               | Cryotherapy: freeze time (30-25 s) MA: 15 mg/kg/day     | Cryotherapy: on the lesion until 1-2 mm of surrounding normal tissue appeared frozen Intramuscular Every two weeks | Every day for 3 weeks | Likely efficacious | Acceptable risk without specialized monitoring | Possibly useful | Farajzadeh et al., 2015 |
| MA + (LEISH-F1 + MPL-SE)       | LEISH-F1: 5, 10 or 20 μg + 25 μg MPL-SE. MA: 10 mg/ Sb<sup>5+</sup>/kg/day. | LEISH-F1: SUB – 3 times. LEISH-F1: On day 0, 28 and 56. MA: The first 10-days cycle on Day 0. Additional cycles on days 21, 42, and 63 | Likely efficacious | Acceptable risk with specialized monitoring | Possibly useful | Nascimento et al., 2010 |
| MA + GM-CSF                    | GM-CSF: 1-2 mL (10 μg/mL). MA: 20 mg Sb<sup>5+</sup>/kg/day. | GM-CSF: topical – 3 times per week. MA: IV – daily. GM-CSF: 3 weeks MA: 20 days | Efficacious | Acceptable risk without specialized monitoring | Investigational | Almeida et al., 2005 |
### Table 4: Continued.

| Treatment                  | Dose                        | Route of Administration/Time                                           | Time         | Efficacy            | Safety                          | Practice/clinical implications       | Study source                  |
|-----------------------------|-----------------------------|------------------------------------------------------------------------|--------------|---------------------|---------------------------------|--------------------------------------|-------------------------------|
| MA + OM                     | MA: 30mg/kg/day OM: 40mg    | MA: IM - daily OM: oral - daily                                        | MA: 3 weeks  | Likely efficacious  | Acceptable risk with specialized monitoring | Clinically useful                | Nilloforoushzadeh et al., 2008 |
|                            |                             | MA: Intradermally in each one centimeter square of a lesion until blanching occurred intralesional, once weekly. Silver dressing: topical – once daily |              |                     |                                 |                                      |                               |
| il MA + silver PD           | MA: il                      | MA: Intradermally in each one centimeter square of a lesion until blanching occurred intralesional, once weekly. Silver dressing: topical – once daily | 42 days      | Not efficacious     | Acceptable risk with specialized monitoring | Investigational                 | Khatami et al., 2013          |
|                            |                             | il: Silver PD: on the lesion                                          |              |                     |                                 |                                      |                               |
| il MA + topical honey       | MA: il                      | MA: il enough to blanch the lesion and 1 mm rim of the surrounding normal skin, once weekly. Honey: topical – twice daily | Until complete healing or for maximum 6 weeks | Not efficacious     | Insufficient evidence          | Investigational                 | Nilloforoushzadeh et al., 2007 |
|                            |                             | il: Honey: soaked gauze                                               |              |                     |                                 |                                      |                               |
| il MA + cryotherapy         | MA: (0.5 – 2 ml)            | Cryotherapy: on the lesion until 2-3 mm halo forms around, weekly, before IL MA. MA: intradermally, all directions, until the lesion had completely blanched, weekly. | Until complete cure or for up to 12 weeks | Likely efficacious | Acceptable risk without specialized monitoring | Possibly useful                | Meymandi et al., 2011         |
| SSG + (LEISH-F1 + MPL-SE)   | LEISH-F1: 5, 10 or 20 μg + 25 μg MPL-SE. SSG: 20mg/kg/day | LEISH-F1: SUB – 3 times. SSG: IV – daily | LEISH-F1: On day 0, 28 and 56. SSG: day 0 to 27 | Efficacious | Acceptable risk with specialized monitoring | Investigational                 | Llanos Cuentas et al., 2010   |
| SSG + IM                    | IM: 5% cream. SSG: 20 mg/kg/day | IM: Topical - 3 times per week. SSG: IV – daily. | IM: 20 days  | Efficacious         | Acceptable risk without specialized monitoring | Clinically useful                | Miranda-Verastegui et al., 2009 |
| il SSG (100 mg/mL), the dose varied between 0.3-3.0 mL. Maximum dose 20mg/Kg/day. | il: Infiltrated in multiple sites until complete blanching and a 1-mm wide ring of the surrounding normal skin. im: one injection on days 1, 3, 5 in one session - up to 3 cycles. | il SSG on days 1, 3, 5 in one session - up to 3 cycles. | Efficacious | Acceptable risk with specialized monitoring | Possibly useful                | El-Sayed & Anwar, 2010         |
| il SSG + im SSG             | il SSG (a part of the dose 20mg/Kg/day already given provided to IL SSG in the same days). | il: Infiltrated in multiple sites until complete blanching and a 1-mm wide ring of the surrounding normal skin. im: one injection on days 1, 3, 5 in one session - up to 3 cycles. |             |                     |                                 |                                      |                               |
| Treatment       | Dose                                                                 | Route of Administration/Time                                                                 | Time                                                                 | Efficacy   | Safety               | Practice/clinical implications | Study source         |
|-----------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------|----------------------|--------------------------------|------------------------|
| il SSG + KE     | il SSG (100mg/mL), the dose varied between 0.3-3.0 mL, maximum dose 20mg/Kg/day. il: Infiltrated in multiple sites until complete blanching and a 1-mm wide ring of the surrounding normal skin. KE: 200 mg. KE: 3 times daily. | il: on days 1, 3, 5 in one session - up to 3 cycles.                                       | Efficacious                                        | Acceptable risk with specialized monitoring | Possibly useful                  | El-Sayed & Anwar, 2010 |
| il SSG + cryotherapy | il SSG: 1-2ml. il SSG: into margin of each lesion, all around, until blanching with cryotherapy preceding the first injection. | il SSG: 3 injections SSG with intervals of 1-3 days.                                    | Efficacious                                        | Acceptable risk without specialized monitoring          | Clinically useful                     | van Thiel et al., 2010  |

MA, meglumine antimoniate; PE, pentoxifylline; GM-CSF, granulocyte macrophage colony-stimulating factor; IM, imiquimod; il SSG, intralesional sodium stibogluconate; im SSG, intramuscular sodium stibogluconate; KE, ketoconazole; il MA (intralesional meglumine antimoniate); nonsilver PD, nonsilver containing polyester dressing; silver PD, silver containing polyester dressing; SSG, sodium stibogluconate; LEISH-F1, lyophilized LEISH-F1 protein; MPL-SE, adjuvant; OM, omeprazole; IV, intravenous; IM, intramuscular; SUB, subcutaneously.
Articles identified through database searching (n=4,725)

Records identified after applying filters (Abstract; Humans; English; Clinical Trial) (n=363)

Records after removal of duplicates (n=311)

Excluded articles (n=221)
- Visceral leishmaniasis/Kala-azar (n=91)
- Did not meet the goals of the study (n=90)
  - No human subjects (n=20)
  - In vitro studies (n=9)
  - Review articles (n=9)
- Related the Leishmania species to the response to treatment (n=1)
- Case report (n=1)

Articles assessed in full text for eligibility (n=90)

Full text articles excluded for not meeting the goals of the study (n=74)

Full text articles included in the systematic review (n=16)

**Figure 1:** Flow diagram of study selection for the systematic review.
Cuestas et al. 2010); intrallesiional sodium stibogluconate plus ketoconazole (90%) (El-Sayed and Anwar 2010); meglumine antimoniate plus omeprazole (89%) (Nilforoushzadeh et al. 2008); MA and pentoxifylline (82%) (Machado et al. 2007); meglumine antimoniate plus LEISH-Fi + MPL-SE (80%) (Nascimento et al. 2010); intrallesiional sodium stibogluconate plus cryotherapy (78%) (Meymand et al. 2011); sodium stibogluconate plus imiquimod (75%) (Miranda-Verastegui et al., 2009); and meglumine antimoniate plus imiquimod (72%) (Miranda-Verastegui et al. 2005). It is important to note that most combinations that showed high cure rates (70-100%) were combinations of pentavalent antimonial with some immunomodulators.

Relapse or recurrence, when reported, was higher in the groups treated with pentavalent antimonial alone and varied from 0 to 38% (Llanos Cuestas et al., 2010; Nascimento et al., 2010 [22, 25]). For the associated groups, only four associations presented relapse or recurrence, and these rates ranged from 0 to 11.1% (Firooz et al. 2006; Van-Thiel et al. 2010 [28, 29]) (Table 2).

No serious adverse effects were observed in patients treated with the drugs combination. For the combination of imiquimod and meglumine antimoniate, adverse effects were locally limited, being the most reported pruritus/itching, erythema, and edema. For the combination of imiquimod with sodium stibogluconate, the same was observed. Only Miranda-Verastegui et al. (2005) [23] reported elevated liver enzyme levels.

In relation to granulocyte macrophage-stimulating factor, there were no reports of side effects. With lyophilized LEISH-Fi protein in association to meglumine antimoniate, the observed side effects were induration, erythema, and tenderness; in combination with sodium stibogluconate, the presence of induration, erythema, and tenderness sites was reported, in addition to headache pyrexia and systemic malaise. The common adverse effects of the use of meglumine antimoniate and sodium stibogluconate were also observed.

To the combination of meglumine antimoniate and pentoxifylline, the common adverse effects, described in two studies, were nausea, arthralgia, dizziness, pain, and diarrhea.

In the use of intrallesiional sodium stibogluconate, alone or in association with other medicinal products, secondary infection, pain and swelling at injection site, and lymphatic involvement were observed. The pentavalent intrallesiional antimonials also showed adverse effects related to the application site, such as pain, pruritus/itching, and edema.

Intralesional sodium stibogluconate, when associated with cryotherapy, resulted in secondary infection and lymphatic involvement, in addition to the inherent symptoms of intralesional application of stibogluconate already mentioned. Meglumine antimoniate combined with silver PD presented only itching, burning, and edema, in contrast to when combined with topical honey, in which only dermatitis, caused by honey, was reported. Cryotherapy combined with meglumine antimoniate had only local adverse effects such as hyperpigmentation plus trivial scar, atrophic scar, and hypopigmentation plus trivial scar (Table 3).

Each of the combinations was classified according to their efficacy (efficacious/likely efficacious/not efficacious) and the clinical implications (investigational/clinically useful/possibly useful) [30].

In this context, imiquimod associated with meglumine antimoniate (Miranda-Verastegui et al. 2005 [23]) and stibogluconate (Miranda-Verastegui et al. 2009 [24]) and cryotherapy-associated stibogluconate (Van-Thiel et al. 2010 [29]) were classified as clinically useful and with acceptable risk without specialized monitoring. The meglumine antimoniate associated with pentoxifylline (Machado et al. 2007) were classified as clinically useful and with acceptable risk with specialized monitoring (Machado et al. 2007 [15]). On the other hand the combination of meglumine antimoniate associated with pentoxifylline performed by Brito et al. 2017 [31] to treat cutaneous leishmaniasis caused by Leishmania braziliensis was classified as not efficacious and not useful. Meglumine antimoniate associated with omeprazole (Nilforoushzadeh et al. 2008 [26]) was classified as clinically useful and with acceptable risk with specialized monitoring.

Some combinations have been classified as possibly useful with acceptable risks without specialized monitoring, such as cryotherapy combined with meglumine antimoniate (Fara-jzadeh et al. 2015 [32]) and the intralesional meglumine antimoniate with cryotherapy (Meymandi et al. 2011 [10]). The combination LEISH-Fi + MPL-SE plus meglumine antimoniate (Nascimento et al. 2010 [25]) and sodium stibogluconate with ketoconazole (El-Sayed and Anwar 2010 [21]) was classified as possibly useful and with an acceptable risk with specialized monitoring.

GM-CSF plus meglumine antimoniate (Almeida et al. 2005 [19]) was still classified as investigational and with acceptable risk without specialized monitoring, while other combinations were classified as investigational, but with acceptable risk with specialized monitoring, such as: imiquimod plus meglumine antimoniate (Arevalo et al., 2007 [20]), Leish-Fi+ MPL-SE plus sodium stibogluconate (Llanos Cuestas et al. 2010 [22]), meglumine antimoniate combined with silver PD (Khatami et al. 2013 [27]), and imiquimod plus meglumine antimoniate (Firooz et al. 2006 [28]). The evidence provided by the study with the combination of intrallesiional meglumine antimoniate and topical honey was insufficient to classify this combination in relation to safety (Table 4).

Regarding effectiveness, only three combinations were classified as noneffective; intrallesiional meglumine antimoniate associated with topical honey performed by Nilforoushzadeh et al. (2007) [33], intrallesiional meglumine antimoniate associated with silver PD tested by Khatami et al. (2013) [27], and pentoxifylline plus meglumine antimoniate performed by Brito et al. (2017). The other combinations were classified as “efficacious” or “likely efficacious”.

4. Discussion

In this review, we saw that the majority of the combinations resulted in an elevated cure rate. Relapse or recurrence, when reported, were higher in the groups treated with the isolated drugs than in the ones treated with the drugs combination. These findings indicate that the combinations with
pentavalent antimonials were more efficacious to prevent relapse or recurrence. Several authors have demonstrated that the combination of some drugs with pentavalent antimonial showed a higher percentage of cure.

4.1. Pentavalent Antimonials. Pentavalent antimonials are considered the first line drugs to treat CL, but they have collateral effects and, in some cases, low cure rate. According to a systematic review by Tuon et al. (2008) [34], meglumine antimoniate (MA), in the recommended dose (20 mg/kg/day), presents an average cure of 76.5%. However, among the studies evaluated by Tuon et al. (2008) [34] and other studies, meglumine antimoniate (20 mg/kg/day) cure rates are quite variable: 40.4% [7, 16], 56.9% [35], 69.4% [7], 79% [36], 84% [5], 85% [37], and 100% [38, 39].

For sodium stibogluconate (SSG), the cure rate shown by Tuon et al. (2008) [34] was of 75.5% in different dosages, with a maximum dose of 20 mg/kg/day. However, the efficacy for this pentavalent antimonial is also variable, being reported rates of 53% [24], 56% [40], 70% [41], and 100% [22, 42].

It is known that the use of systemic meglumine antimoniate can lead to serious adverse effects, so the application in the lesion site showed to be an efficacious and more secure alternative to treat CL. Some authors have demonstrated that the intralesional MA is as effective as the systemic MA and had few adverse effects [43–45]. It is important to note that, unlike in the articles included in this study, Vasconcellos et al. (2014) [46] reported that one patient presented eczema after the treatment with intralesional meglumine antimoniate. After use of oral dexchlorpheniramine, eczema and ulcer receded. Thus, the administration of intralesional MA must be carefully conducted, especially due to the possibility of occurring hypersensitivity.

For the SSG, the intralesional application has also shown good results [47, 48]. The application twice a week is well tolerated and the lesions healed faster than only once a week [49].

4.2. Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). The granulocyte macrophage colony-stimulating factor (GM-CSF) acts in the recruitment of monocytes and neutrophils. It is produced by a wide range of cells such as macrophages, neutrophils, dendritic cells, T cells, eosinophils, fibroblasts and endothelial cells. It is also believed that it promotes the differentiation of the macrophages to a proinflammatory phenotype [50].

In view of its role in the recruitment of different types of cells, GM-CSF has been investigated for the CL treatment. In their study, Almeida et al. (2005) [19] evaluated the topical use of GM-CSF (10 μg/mL) in combination with the meglumine antimoniate (20 mg/kg/day) and showed that 60% of the patients were clinically healed 50 days after the treatment start, and the remaining 40% were cured 120 days after the beginning of the treatment. Similar results were found by Santos et al. (2004) [51], when they use this combination. On the other hand, among the patients treated only with meglumine antimoniate, just 20% were clinically healed at 45 days after the start of treatment, and 100% of the patients were cured after 256 days.

In a previous study, Almeida et al. (1999) [52] showed that clinical cure in patients treated with the combination of pentavalent antimonial and GM-CSF was faster than in the control group that was treated with pentavalent antimonial alone. Possibly the factor that contributed for the quick cure associated by GM-CSF was the modulation of the immunologic balance, by inducing differentiation for the Th1 subtype [52–54] and activation of macrophages to kill Leishmania [55].

GM-CSF combined with pentavalent antimonial can be an alternative to treat CL, since the risk inherent to this combination is acceptable and its use deserves to be greatly investigated.

4.3. Imiquimod. Imiquimod is an immunomodulator that was first approved to treat genital and perianal warts and then to treat actinic keratosis.

Imiquimod stimulates the immune system in different ways. It is believed that imiquimod is an agonist of the toll like receptors 7 and 8, so the stimulation of these receptors leads to the synthesis of different inflammatory mediators, such as INF-α, TNF-α, interleukins 1, 6, 8, 10 and 12, granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor [56–58]. In addition, the use of imiquimod also indirectly contributes to the immune response acquired, through the induction of Th1 type cytokines, such as INF-Y [58, 59]. The induction of INF-Y an IL-12 production induces to Th1 differentiation and it is important in the control of CL.

Imiquimod has been investigated in the treatment of CL and its efficacy is controversial. Arevalo et al. (2007) [20] and Seeberger et al. (2003) [60] showed no efficacy in the use of imiquimod alone. In combination with pentavalent antimonials, imiquimod can be an adjuvant; moreover, the success in treatment with imiquimod is directly related to the concentration used. Only at the concentration of 7.5% imiquimod combined with meglumine antimoniate appears to be more effective than the antimonate alone [20]. Authors that administered imiquimod at 5% in combination with meglumine antimoniate observed that the efficacy was similar to that of patients treated with meglumine antimoniate alone [23, 28].

However, when Miranda-Verastegui et al. (2009) [24] used imiquimod 5% combined with sodium stibogluconate, the combination was more effective than sodium stibogluconate alone.

Meymandi et al. (2011) [61] showed the combination of intrallesional meglumine antimoniate and imiquimod as beneficial its resulted in a decrease in parasitic load, an increase in lymphocyte numbers, and a decrease in histiocyte aggregation in the lesion site. In addition, they observed that imiquimod alone was also ineffective. Imiquimod appears to be a good adjuvant for pentavalent antimonial when used in the appropriate concentration. The risk involved in its use is acceptable. More evidence is needed to strengthen its application in clinical practice.

4.4. Silver-Containing Polyester Dressing. The silver-containing polyester dressing (silver PD) is composed of hydrophobic polyamide netting with silver-coated fibers. Silver PD
differs from each other by the way silver is incorporated and how it is liberated in the lesion. It is known that silver has antimicrobial activity in solutions, but it does not differentiate at pathogens from the other cells, such as fibroblast and keratinocytes [62, 63].

Clinical trials using silver PD to treat CL are scarce. In this review, only one study used silver PD with this aim. No efficacy in silver PD was shown, not even combined with intraleisonal meglumine in the treatment of CL [27]. In this study, silver PD Atrauman Ag® by Hartmann was used.

As mentioned before, silver can cause the death of human cells [63]. However, according to the manufacturer of the Atrauman Ag®, a higher concentration of silver is needed to lead to the death of human cells and, specifically in the case of Atrauman Ag®, the release of silver is small. Moreover this dressing released silver only when in contact with bacteria and no negative influence of the silver ions was exercised in human cells [64]. Since amastigote forms are phagocytosed by macrophages, they remaining and multiplying. The silver released by the dressing, for being in small quantities, may not be able to reach the amastigotes phagocytosed.

There are some inherent characteristics of polyester dressing that influence in their activity, such as their capacity in the release of silver [65]. Besides that, the compounds binding to silver can contribute to this activity.

The use of silver PD isolated or in combination with pentavalent antimonial needs to be further investigated due to the scarcity of studies that used silver PD to treat CL and the several factors that can influence its efficacy.

4.5. LEISH-F1+MPL-SE. LEISH-F1+MPL-SE was the first candidate vaccine for entry in clinical trials. It was composed by recombinant fusion protein Leish-IIIIF and an adjuvant in an oil-water emulsion (monophosphoryl lipid A - MPL). MPL is a TLR4 agonist, safely used in other vaccines, such as hepatitis [66].

Authors demonstrated that LEISH-F1+MPL-SE was safe, immunogenic, and effective in inducing the production of IgG antibodies, INF-Y, and other cytokines in humans and mice [67–69].

In the two articles included in this review, LEISH-F1+MPL-SE was tested in combination with SSG or meglumine antimoniate in the treatment of CL. One of these Llanos Cuestas et al. (2010) [22] observed similarly clinical cure in both groups; however in addition, relapse or recurrence did not occur in the combination groups. The stimulation of the immune response was greater in the LEISH-F1+MPL-SE group than in the SSG group, a fact that may have contributed to the absence of recurrences.

Nascimento et al. (2010) [25], on the other hand, observed a greater clinical cure rate (80%) in the group treated with the combination of LEISH-F1+MPL-SE and meglumine antimoniate than in the groups treated with meglumine antimoniate alone (38%) or the adjuvant MPL-SE alone (50%).

LEISH-F1+MPL-SE in combination with pentavalent antimonials can be useful to treat CL, mainly because this combination appears to decrease recurrences observed with pentavalent antimony alone. The risks related to its use are acceptable therefore its use should be better explored.

4.6. Topical Honey. Honey was used, many years ago to treat several types of lesions, but there is no consensus on its effectiveness in lesion healing. In relation to CL, there are few data on the use of honey for its treatment.

It is well established that honey has an antimicrobial action, which can act on tissues, contributing to their repair [70], and also on the immune system, having both proinflammatory and anti-inflammatory action [71].

FDA has already approved some honey-based products with different clinical indications, but some authors remain cautious regarding its clinical use for lesion healing. Jull et al. (2013) [72], in a review about the use of topical honey in the treatment of wounds, concluded that honey may delay the time of wound healing in some types of wounds, such as CL and deep burns, but it is good for moderate burns. Still, in their opinion, more clinical studies are needed to guide the use of honey in clinical practice in other types of wounds than moderate burns.

In the same line Saikaly and Khachemoune (2017) [73] concluded in their study that the use of honey seems to be beneficial to wound healing in some types of lesions and that new technologies have contributed to the understanding of the action mechanisms of honey. However, more evidence is still needed to elucidate precisely the results obtained with the use of honey.

The combination of topical honey with IL-MA to treat CL was tested by Nilforoushzadeh et al. (2007) [33] and did not show efficacy. In this study, gauze soaked in honey was used, not being mentioned the type of honey used. It is known that there are different types of honey of different constitution and that, therefore, they may have different properties [71]. The choice of dressing must also be taken into consideration, as one should choose the dressing most appropriate for the wound to be treated [70].

There are several factors related to honey that should be taken into account, such as honey type and composition, as well as the best form of application, and it deserves to be better evaluated in order to be combined with pentavalent antimonials in the treatment of CL.

4.7. Omeprazole. Omeprazole is a drug used to treat peptic ulcer disease, due to its interference with the stomach pH. Omeprazole acts by inhibiting the human gastric K⁺, H⁺-ATPase enzyme, resulting in the disruption of acid secretion [74].

In the intracellular environment, omeprazole accumulates in the lysosomes, in the same place that the amastigotes in the macrophages. Jiang et al. (2002) [75] showed that omeprazole inhibits the K⁺, H⁺-ATPase enzyme located on the membrane surface of Leishmania, and this drug had leishmanicidal activity against Leishmania donovani intracellular amastigotes in a dose-dependent manner.

In their study, Nilforoushzadeh et al. 2008 [26] reported that omeprazole (40 mg) plus intramuscular meglumine antimoniate (30 mg/kg/day) showed similar clinical cure
presented by meglumine antimoniate (60 mg/kg/day), being it of 89% and 93%, respectively. Moreover, omeprazole (40 mg) plus intramuscular meglumine antimoniate (30 mg/kg/day) showed greater clinical cure rate than meglumine antimoniate (30 mg/kg/day), being the cure rates of 89% and 80%, respectively.

The combination omeprazole plus meglumine antimoniate was well tolerated and the authors reported no side effects, thus it may be a clinically useful alternative likely efficacious for CL treatment.

4.8. Cryotherapy. Cryotherapy is a therapeutic modality recommended by the World Health Organization (WHO) for the treatment of CL. According to WHO, it is a recommended treatment regimen for Old World CL, combined or not with intralesional antimonial [4].

Above all, some studies showed that the combination of cryotherapy with intralesional pentavalent antimonial is more effective than the antimonial alone [11, 76].

The three articles included in this review, conducted by Van-Thiel et al. (2010) [29], Meymandi et al. (2011) [10] and Farajzadeh et al. (2015) [32], presented a lower cure rate for the combination of cryotherapy and intralesional sodium stibogluconate or for the combination with meglumine antimoniate.

Some variables should be taken into consideration for the performance of cryotherapy, which may directly influence the efficacy of the treatment, such as the size of the lesion and the frequency of the cryotherapy sessions. Papules smaller than or equal to 1 cm, responded more quickly to cryotherapy than lesions larger than 1 cm. According to Ranawaka et al. (2011) [77], for smaller papules the cure rate was 90.5% and for the ones larger than 1 cm, it was 64.28%.

The frequency of sessions also seems to play an important role in the effectiveness of cryotherapy. When performed weekly, cure rates were high (equal or greater than 90%), either alone or in combination with pentavalent antimonials [8, 77]. Application at longer time intervals may result in lower cure rates. Soto et al. (2013) [78] performed only two sessions of cryotherapy at intervals greater than 1 week and obtained a low cure rate (20%).

Another important fact to consider before the application of cryotherapy is the subtype of skin. In patients with phototype V, for example, depigmentation may occur. It is also necessary to investigate the tendency of keloid formation [77].

Cryotherapy is a clinically useful alternative and has few, but not serious, adverse effects. It has a high cure rate when considering the size of the lesion and the frequency of the sessions.

4.9. Ketoconazole. Ketoconazole is an antifungal that interferes with the biosynthesis of ergosterol, an important cell membrane constituent, essential for the viability and survival of fungi and trypanosomatids. The target of Ketoconazole is the CI4α-demethylase and, thus, it interferes with the dimethylation of the sterol and, consequently, inhibits the synthesis of ergosterol [79].

Oral ketoconazole alone has been tested for the treatment of CL for several years and has shown different cure rates [80–83]. In this review, we included the study of El-Sayed and Anwar (2010) [21], which tested the combination of intralesional sodium stibogluconate and oral ketoconazole (600 mg/day). This combination was more effective than the ketoconazole and sodium stibogluconate alone.

Saenz et al. (1990) [80], using ketoconazole alone (600 mg/day), obtained a cure rate of 73% and Salamanpour et al. (2001) [82] found a cure rate of 89% in the treatment with ketoconazole (600 mg/day) alone.

Possibly the species is a determinant factor in the efficacy of ketoconazole. WHO recommends ketoconazole (600 mg/day) as the treatment regimen for CL in the New World, specifically when the etiologic agent is Leishmania mexicana, although there are reports of its efficacy in other species [4]. El-Sayed and Anwar (2010) [21] did not identify the species in their study. Saenz et al. (1990) [80] also did not identify it, but their study was conducted in Panama. Salamanpour et al. (2001) [82] cited that the patients had Old World CL. Ramanathan et al. (2011) [83] demonstrated efficacy in the treatment of CL by Leishmania panamensis. With respect to ketoconazole resistance, Andrade-Neto et al. (2012) [84] demonstrated that Leishmania amazonensis can up-regulate the C-14 demethylase in response to ketoconazole, which may contribute to its resistance to this drug.

Oral administration of ketoconazole combined with intralesional sodium stibogluconate for the treatment of CL is shown acceptable risk with specialized monitoring and no serious adverse effects and in administration are reported.

4.10. Pentoxifylline. Pentoxifylline is a derivative of dimethylxanthine classified as a vasodilator agent. It exerts effects on different cell types, such as reduction of the expression of adhesion molecules with ICAM-1 in keratinocytes and E-selectin in endothelial cells, inhibition of TNF-α synthesis, IL-1 and IL-6 and antifibrinolytic effects [14, 85].

In particular, pentoxifylline may potentiate the action of pentavalent antimonials primarily by two mechanisms: increase in the expression of the inducible nitric oxide synthase (iNOS) and, consequently, increase in the production of nitric oxide, and anti-TNF-α action [86, 87]. Brito et al. (2014) [88] observed that patients treated with pentoxifylline (400 mg - 3 times per day) combined with meglumine antimoniate (20 mg/kg/day) had greater TNF-α suppression than those treated with meglumine antimoniate alone (20 mg/kg/day), and cure rates were higher in the combined group than in the second group.

Machado et al. (2007) [15] demonstrated in their study that the combination of meglumine antimoniate (20 mg/kg/day) and pentoxifylline (400 mg - 3 times per day) potentiated the effect of the meglumine antimoniate, since the combination resulted in 82% of cure in patients with mucosal leishmaniasis, while meglumine antimoniate (20 mg/kg/day) alone had a cure rate of 41.6%. Sadeghian and Nilforoushzadeh (2006) [17], in which this same combination was tested to treat cutaneous leishmaniasis (in endemic area for Leishmania major) and resulted in 81.3% cure versus 51.6% for meglumine antimoniate alone. In contrast, at the same
conditions in the cited studies, Brito et al. (2017) [31] reported a cure rate of 43% for a combination of pentoxifylline and meglumine antimoniate to treat cutaneous leishmaniasis caused by Leishmania braziliensis, as divergences in cure rates may be related to intrinsic characteristics of each patient to pentoxifylline, and the specie of Leishmania.

The anti-TNF-α action of pentoxifylline makes its use interesting, mainly in cases of mucosal and/or treatment-refractory leishmaniasis, since this cytokine is the main responsible for mucosal damage. There have been reports of success in the combination of pentoxifylline and meglumine antimoniate in the treatment of treatment-refractory cases [114] and with high production of TNF-α [89] or recurrent cases [90].

For Lessa et al. (2001) [14], the efficacy of the combination pentoxifylline and meglumine antimoniate should make it the second choice in the treatment, since the administration is oral and has fewer adverse effects than amphotericin B.

The efficacy of pentoxifylline in combination with meglumine antimoniate in the treatment of mucocutaneous leishmaniasis, even in cases refractory to conventional and/or recurrent treatment, added to few and not severe effects, makes this combination a good therapeutic alternative clinically useful for treatment of mucocutaneous leishmaniasis. However to treat cutaneous leishmaniasis with this combination it is necessary to take into account the species involved, since in cases caused by Leishmania braziliensis this combination showed not efficacious and not useful.

4.11. Clinical Implications. The first choice drugs for the treatment of cutaneous or mucocutaneous leishmaniasis do not always show the expected result, so the association of these conventional drugs with others drugs or modalities of therapy, such as local therapies have good cure rates, often higher than those of the drugs of choice, and few adverse effects. Above all, the combination with immunomodulators seems to be promising, even with limited numbers study and patient it was surprisingly effective, revealing higher efficacy and few adverse effects. In the case of combination with local application therapies, the diameter of the lesion appears to be an important factor for successful treatment. In addition to efficacy, many combinations are easy to administer by the patient and without the need for specialized monitoring, what represents an advantage for use in more isolated communities.

4.12. Strengths and Limitations of the Study. This systematic review has gone through many steps in its development. The precision in publications’ search was guaranteed by two databases. Publications’ identification criteria were monitored and discussed in many steps of the research to guarantee robustness and rigor of the findings. Special care was also taken for the identification of the MeSH terms, which were decided by many researchers and by consensus, providing good sensitivity and specificity. The publications’ findings were organized and detailed in four tables for better clarity and quality of data. Concerning the limitations, we identified that only four of the 16 articles included in the review highlighted the limitations topic (Llanos Cuestas et al. 2010; Khatami et al. 2013; Farajzadeh et al. 2015; Brito et al. 2017). Other limitations were the inclusion of only two databases, with publications merely in English comprising the period from 12/2004 to 6/2017. The considerable heterogeneity between the articles included, mainly due to the significant variation of both the substances used and the research regions, made it impossible to analyze the data more precisely, for example through meta-analysis. Despite these limitations, we believe the results can contribute positively for the treatment of cutaneous leishmaniasis and mucocutaneous leishmaniasis.

5. Conclusion

The combination of pentavalent antimonial drugs with other drugs seems to be a good alternative to conventional treatment, since they presented good cure rates, often higher than those of the drugs of choice, and few adverse effects. Therefore, this type of combination deserves to be investigated in more detail by clinical trials and prospective studies with more robust population sample to reinforce the effectiveness and safety that this alternative treatment provides to the patient.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior for the financial support. A summary version of this work, with the same title, was presented orally at the V International Congress of the CCS held in Maringá, Brazil, in 2018. Therefore, the authors thank the congress organizing committee for this.

References

[1] WHO, *Neglected tropical diseases*, 2016, http://www.who.int/neglected_diseases/news/WHO_implement_epidemiological_surveillance_leishmaniasis/en/.

[2] WHO, *Leishmaniasis*, 2017, http://www.who.int/mediacentre/factsheets/fs375/en/.

[3] J. Blum, D. N. Lockwood, L. Visser et al., “Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis,” *International Health*, vol. 4, no. 3, pp. 153–163, 2012.

[4] World Health Organization, *Control of the leishmaniases*, World Health Organ Tech Rep Ser, 2010, http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf.

[5] E. M. Andersen, M. Cruz-Saldarriaga, A. Llanos-Cuestas et al., “Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis,” *The American Journal of Tropical Medicine and Hygiene*, vol. 72, pp. 133–137, 2005.
[6] I. Kevric, M. A. Cappel, and J. H. Keeling, “New world and old world leishmaniasis infections: a practical review,” *Dermatologic Clinics*, vol. 33, no. 3, pp. 579–593, 2015.

[7] G. A. S. Romero, M. V. De Farias Guerra, M. G. Paes, and V. De Oliveira Macêdo, “Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate,” *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 5, pp. 456–465, 2001.

[8] E. Negera, E. Gadisa, J. Hussein et al., “Treatment response of cutaneous leishmaniasis due to *Leishmania aethiopica* to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 106, no. 8, pp. 496–503, 2012.

[9] N. Safi, G. D. Davis, M. Nadir, H. Hamid, L. L. Robert, and A. J. Case, “Evaluation of Thermotherapy for the Treatment of Cutaneous Leishmaniasis in Kabul, Afghanistan: A Randomized Controlled Trial,” *Military Medicine*, vol. 177, no. 3, pp. 345–351, 2012.

[10] S. Shamis Meymandi, S. Zandi, H. Aghaie, and A. Heshmatkhah, “Efficacy of CO₂ laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate,” *Journal of the European Academy of Dermatology and Venereology*, vol. 25, no. 5, pp. 587–591, 2011.

[11] A. Asilian, A. Sadeghinia, G. Faghihi, and A. Momeni, “Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis,” *International Journal of Dermatology*, vol. 43, no. 4, pp. 281–283, 2004.

[12] A. Asilian and M. Davami, “Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial,” *Clinical and Experimental Dermatology*, vol. 31, no. 5, pp. 634–637, 2006.

[13] R. Reithinger, M. Mohsen, M. Wahid et al., “Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis Caused by Leishmania tropica in Kabul, Afghanistan: A Randomized Controlled Trial,” *Clinical Infectious Diseases*, vol. 40, pp. 1148–1155, 2005.

[14] E. M. Carvalho, H. A. Lessa, F. Lima et al., “Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony,” *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 2, pp. 87–90, 2001.

[15] P. R. Machado, H. Lessa, M. Lessa et al., “Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis,” *Clinical Infectious Diseases*, vol. 44, pp. 788–793, 2007.

[16] L. Dastgheib, M. Naseri, and Z. Mirashe, “Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: A randomized controlled clinical trial,” *International Journal of Dermatology*, vol. 51, no. 12, pp. 1508–1511, 2012.

[17] G. Sadeghian and M. A. Niforouzhashadeh, “Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis,” *International Journal of Dermatology*, vol. 45, no. 7, pp. 819–821, 2006.

[18] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation,” *British Medical Journal*, vol. 349, Article ID g6745, 2015.

[19] R. P. Almeida, J. Brito, and P. L. Machado, “Successful treatment of refractory cutaneous leishmaniasis with gm-csf and antimonials,” *The American Journal of Tropical Medicine and Hygiene*, vol. 73, no. 1, pp. 79–81, 2005.

[20] I. Arevalo, G. Tulliano, A. Quispe et al., “Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis,” *Clinical Infectious Diseases*, vol. 44, no. 12, pp. 1549–1554, 2007.

[21] M. El-Sayed and A. Anwar, “Intralosional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: A comparative study,” *Journal of the European Academy of Dermatology and Venereology*, vol. 24, no. 3, pp. 335–340, 2010.

[22] A. Llanos-Cuentas, W. Calderón, M. Cruz et al., “A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis,” *Vaccine*, vol. 28, no. 46, pp. 7427–7433, 2010.

[23] C. Miranda-Verástegui, A. Llanos-Cuentas, I. Arévalo, B. J. Ward, and G. Matlashewski, “Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru,” *Clinical Infectious Diseases*, vol. 40, no. 10, pp. 1395–1403, 2005.

[24] C. Miranda-Verastegui, G. Tulliano, T. W. Gyorkos et al., “First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony,” *PLOS Neglected Tropical Diseases*, vol. 3, no. 7, article e491, 2009.

[25] E. Nascimento, D. F. Fernandes, E. P. Vieira et al., “A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis,” *Vaccine*, vol. 28, no. 40, pp. 6581–6587, 2010.

[26] M. A. Niforouzhashadeh, F. Jaffary, N. Ansari, A. H. Siadat, Z. Niforoushahan, and A. Firouz, “A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis,” *Journal of Vector Borne Diseases*, vol. 45, no. 4, pp. 287–291, 2008.

[27] A. Khatami, R. Talaee, M. Rahshenas et al., “Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial,” *PLoS ONE*, vol. 8, no. 6, 2013.

[28] A. Firooz, A. Khamesipour, M. H. Ghoorchi et al., “Imiquimod in Combination With Meglumine Antimoniate for Cutaneous Leishmaniasis,” *JAMA Dermatology*, vol. 142, no. 12, 2006.

[29] P.-P. Van Thiel, T. Leenstra, H. J. De Vries et al., “Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in Northern Afghanistan: Epidemiology, clinical aspects, and treatment,” *The American Journal of Tropical Medicine and Hygiene*, vol. 83, no. 6, pp. 1295–1300, 2010.

[30] P. W. Nassif, T. F. F. De Mello, T. R. Navasconi et al., “Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: A systematic review,” *Parasitology*, vol. 144, no. 8, pp. 995–1004, 2017.

[31] E. M. de Carvalho, L. H. Guimarães, P. R. Machado et al., “Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis,” *The American Journal of Tropical Medicine and Hygiene*, vol. 33, no. 3, pp. 579–593, 2012.
Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: A randomized clinical trial, Iranian Journal of Parasitology, vol. 10, no. 1, pp. 1–8, 2015.

N. E. Aronson, G. W. Wortmann, W. R. Byrne et al., "Comparison of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis," BMC Complementary and Alternative Medicine, vol. 7, article 13, 2007.

F. F. Tuon, V. S. Amato, M. E. Siqueira, A. C. Nicodemo, and V. A. Neto, "Treatment of New World cutaneous leishmaniasis - A systematic review with a meta-analysis," International Journal of Dermatology, vol. 47, no. 2, pp. 109–124, 2008.

L. O. Neves, E. Priscilla, N. Gadelha et al., "A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis," Anais Brasileiros de Dermatologia, vol. 86, pp. 1092–1101, 2011.

J. Soto, L. Valda-Rodriguez, J. Toledo et al., "Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis," The American Journal of Tropical Medicine and Hygiene, vol. 71, no. 5, pp. 577–581, 2004.

L. López, M. Robayo, M. Vargas, and ID. Vélez, "Thermotherapy: An alternative for the treatment of American cutaneous leishmaniasis," Trials, vol. 3, pp. 2–7, 2012, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3441257&tool=pmcentrez&rendertype=abstract.

M. E. C. Dorval, E. T. Oshiro, E. Cupollillo, A. C. C. Castro, and T. P. Alves, "Ocorrência de leishmaniose tegumentar americana no Estado do Mato Grosso do Sul associada à infecção por Leishmania (Leishmania) amazonensis," Journal of the Brazilian Society of Tropical Medicine, vol. 39, no. 1, pp. 43–46, 2006.

V. A. Laguna-Torres, C. A. C. Silva, D. Correia, E. M. Carvalho et al., "Efficacy of melofloxine in the treatment of skin leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis," Revista da Sociedade Brasileira de Medicina Tropical, vol. 32, pp. 529–533, 1999, http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L29526791.

N. E. Aronson, G. W. Wortmann, W. R. Byrne et al., "A Randomized Controlled Trial of Local Heat Therapy Versus Intravenous Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis major Infection," PLOS Neglected Tropical Diseases, vol. 4, no. 3, p. e628, 2010.

M. Solomon, F. Pavlotzky, A. Barzilai, and E. Schwartz, "Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers," Journal of the American Academy of Dermatology, vol. 68, no. 2, pp. 284–289, 2013.

G. Wortmann, R. S. Miller, C. Oster, J. Jackson, and N. Aronson, "A Randomized, Double-Blind Study of the Efficacy of a 10- or 20-Day Course of Sodium Stibogluconate for Treatment of Cutaneous Leishmaniasis in United States Military Personnel," Clinical Infectious Diseases, vol. 35, no. 3, pp. 261–267, 2002.

M. I. F. Pimentel, É. D. C. F. e Vasconcellos, C. D. O. Ribeiro et al., "Intralesional treatment with meglumine antimoniate in three patients with new world cutaneous leishmaniasis and large periarticular lesions with comorbidities," Journal of the Brazilian Society of Tropical Medicine, vol. 50, no. 2, pp. 269–272, 2017.

R. E. da Silva, A. Toledo Júnior, M. C. Senna, A. Rabello, and G. Cota, "Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre," Memórias do Instituto Oswaldo Cruz, vol. 111, pp. 512–515, 2016, http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762016000800512&amp;lng=en&amp;nrm=iso&amp;tlng=en.

É. D. C. Ferreira E Vasconcellos, M. I. Fernandes Pimentel, A. De Oliveira Schubach et al., "Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006)," The American Journal of Tropical Medicine and Hygiene, vol. 87, no. 2, pp. 257–260, 2012.

E. D. C. F. e Vasconcellos, M. I. F. Pimentel, C. M. Valete-Rosalino, M. D. F. Madeira, and A. D. O. Schubach, "Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate," Revista do Instituto de Medicina Tropical de Sao Paulo, vol. 56, no. 4, pp. 361–362, 2014.

R. A. Bumb, N. Prasad, K. Khandelwal et al., "Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India," British Journal of Dermatology, vol. 168, no. 5, pp. 1114–1119, 2013.

R. R. Ranawaka and H. S. Weerakoon, "Randomized, double-blind, comparative clinical trial on the efficacy and safety of intraleosomal sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani," Journal of Dermatological Treatment, vol. 21, no. 5, pp. 286–293, 2010.

R. A. Bumb, R. D. Mehta, B. C. Ghiya et al., "Efficacy of short-duration (twice weekly) intraleosomal sodium stibogluconate in treatment of cutaneous leishmaniasis in India," British Journal of Dermatology, vol. 163, no. 4, pp. 854–858, 2010.

I. Ushach and A. Zlotnik, "Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage," Journal of Leukocyte Biology, vol. 100, no. 3, pp. 481–489, 2016.

J. B. Santos, A. R. De Jesus, P. R. Machado et al., "Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: A randomized, double-blind, placebo-controlled study," The Journal of Infectious Diseases, vol. 190, no. 10, pp. 1793–1796, 2004.

R. Almeida, A. D’Oliveira Jr., P. Machado et al., "Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis," The Journal of Infectious Diseases, vol. 180, no. 5, pp. 1735–1737, 1999.

R. Badaro, I. Lobo, M. Nakatani et al., "Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report," The Brazilian Journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, vol. 5, no. 4, pp. 223–232, 2001.

T. Doher and R. L. Coffman, "Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major," The Journal of Immunology, vol. 150, pp. 5476–5483, 1993.
[55] W. Y. Weiser, A. Van Niel, S. C. Clark, David. J. R. et al., "Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages," The Journal of Experimental Medicine, vol. 166, pp. 1436–1446, 1987, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2189637&tool=pmcentrez&rendertype=abstract.

[56] C. E. Weeks and S. J. Gibson, "Induction of Interferon and Other Cytokines by Imiquimod and Its Hydroxylated Metabolite R-842 in Human Blood Cells In Vitro," Journal of Interferon & Cytokine Research, vol. 14, no. 2, pp. 81–85, 1994.

[57] S. J. Gibson, L. M. Imbertson, T. L. Wagner et al., "Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609," Journal of Interferon & Cytokine Research, vol. 15, no. 6, pp. 537–545, 1995.

[58] E. Hanna, R. Abadi, and O. Abbasi, "Imiquimod in dermatology: an overview," International Journal of Dermatology, vol. 55, no. 8, pp. 831–844, 2016.

[59] A. Weber, C. Zimmermann, A. K. Mausberg, B. C. Kie-seier, H. P. Hartung, and H. H. Hofstetter, "Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod," International Immunopharmacology, vol. 17, no. 2, pp. 427–431, 2013.

[60] J. Seeberger, S. Daoud, and J. Pammer, "Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod," International Journal of Dermatology, vol. 42, no. 7, pp. 576–579, 2003.

[61] S. Shamsi Meymandi, A. Javadi, S. Dabiri, M. Shamsi Mey-mandi, and M. Nadji, "Comparative histological and immuno-histochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy," Archives of Iranian Medicine, vol. 14, no. 4, pp. 238–243, 2011.

[62] L. W. Toy and L. Macera, "Evidence-based review of silver dressing use on chronic wounds," Journal of the American Association of Nurse Practitioners, vol. 23, no. 4, pp. 183–192, 2011.

[63] V. K. M. Poon and A. Burd, "In vitro cytotoxicity of silver: implication for clinical wound care," Burns, vol. 30, no. 2, pp. 140–147, 2004.

[64] Hatmann, Atrauman * Ag – Questions and Answers Content, https://export.catalog.hartmann.info/ph-images/content/ img_27085_30.pdf.

[65] R. White, "Efficacy of silver-containing dressings," Journal of Wound Care, vol. 15, no. 9, pp. 417–418, 2006.

[66] M. S. Dutthie, V. S. Raman, F. M. Piazza, and S. G. Reed, "The development and clinical evaluation of second-generation leishmaniasis vaccines," Vaccine, vol. 30, no. 2, pp. 134–141, 2012.

[67] J. Chakravarty, S. Kumar, S. Trivedi et al., "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis," Vaccine, vol. 29, no. 19, pp. 3531–3537, 2011.

[68] I. D. Vélez, K. Gilchrist, S. Martinez et al., "Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis," Vaccine, vol. 28, no. 2, pp. 329–337, 2009.

[69] R. N. Coler, Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed, "Leish-III, a recombinant polypeptide vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells," Infection and Immunity, vol. 75, no. 9, pp. 4648–4654, 2007.

[70] P. Molan, "The evidence and the rationale for the use of honey as a wound dressing," Wound Practice & Research, vol. 19, pp. 204–220, 2011.

[71] J. Majtan, "Honey: An immunomodulator in wound healing," Wound Repair and Regeneration, vol. 22, no. 2, pp. 187–192, 2014.

[72] A. B. Jull, N. Walker, and S. Deshpande, "Honey as a topical treatment for wounds," Cochrane Database of Systematic Reviews, vol. 8, no. 4, Article ID CD005083, 2013.

[73] S. K. Saikaly and A. Khachemoune, "Honey and Wound Healing: An Update," American Journal of Clinical Dermatology, vol. 18, no. 2, pp. 237–251, 2017.

[74] N. J. V. Bell and R. H. Hunt, "Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease," Gut, vol. 33, no. 1, pp. 118–124, 1992.

[75] S. Jiang, J. Meadows, S. A. Anderson, and A. J. Makkada, "Antileishmanial activity of the antiulcer agent omeprazole," Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2569–2574, 2002.

[76] A. Asilian, A. Sadeghinia, G. Faghhihi, A. Momeni, and A. Amini Harandi, "The efficacy of treatment with intralesional meglu-mine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishma-niasis," Annals of Tropical Medicine and Parasitology, vol. 97, no. 5, pp. 493–498, 2003.

[77] R. R. Ranawaka, H. S. Weerakoon, and N. Opatheila, "Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis," Journal of Dermatological Treatment, vol. 22, no. 4, pp. 241–245, 2011.

[78] J. Soto, E. Rojas, M. Guzman et al., "Intralesional antimony for single lesions of Bolivian cutaneous Leishmaniasis," Clinical Infectious Diseases, vol. 56, no. 9, pp. 1255–1260, 2013.

[79] W. de Souza, J. Cola, and F. Rodrigues, "Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs," Interdisci-plinary Perspectives on Infectious Diseases, vol. 2009, Article ID 642502, 19 pages, 2009.

[80] R. E. Saenz, H. Paz, and J. D. Berman, "Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishma-niasis," American Journal of Medicine, vol. 89, no. 2, pp. 147–153, 1990.

[81] O. Ozgoztasi and I. Baydar, "A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey," International Journal of Dermatology, vol. 36, no. 1, pp. 61–63, 1997.

[82] R. Salmanpour, F. Handjani, and M. K. Nouthpisheh, "Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (glucantime) for the treatment of cutaneous leishmaniasis," Journal of Dermatological Treatment, vol. 12, no. 3, pp. 159–162, 2001.

[83] R. Ramanathan, K. R. Talat, D. P. Fedorko, S. Mahanty, and T. E. Nash, "A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis," The American Journal of Tropical Medicine and Hygiene, vol. 84, no. 1, pp. 109–117, 2011.

[84] V. V. Andrade-Neto, H. L. de Matos-Guedes, D. C. D. O. Gomes, M. M. do Canto-Cavalheiro, B. Rossi-Bergmann, and E. C. Torres-Santos, "The stepwise selection for ketoconazole resistance induces upregulation of C14-demethylase (CYP51) in Leishmania amazonensis," Memorias do Instituto Oswaldo Cruz, vol. 107, no. 3, pp. 416–419, 2012.

[85] O. Zargari, "Pentoxifylline: A drug with wide spectrum applica-tions in dermatology," Dermatology Online Journal, vol. 14, no. 11, article no. 2, 2008.
[86] K. H. N. Hoebe, N. Gonzalez-Ramon, S. M. Nijmeijer et al., “Differential effects of pentoxifylline on the hepatic inflammatory response in porcine liver cell cultures increase in inducible nitric oxide synthase expression,” *Biochemical Pharmacology*, vol. 61, no. 9, pp. 1137–1144, 2001.

[87] M. Ahmadi and H. Khalili, “Potential benefits of pentoxifylline on wound healing,” *Expert Review of Clinical Pharmacology*, vol. 9, no. 1, pp. 129–142, 2016.

[88] P. R. Machado, M. Dourado, G. Brito et al., “Clinical and Immunological Outcome in Cutaneous Leishmaniasis Patients Treated with Pentoxifylline,” *The American Journal of Tropical Medicine and Hygiene*, vol. 90, no. 4, pp. 617–620, 2014.

[89] A. Báfrica, F. Oliveira, L. A. R. Freitas, E. G. Nascimento, and A. Barral, “American Cutaneous Leishmaniasis unresponsive to antimonial drugs: Successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline,” *International Journal of Dermatology*, vol. 42, no. 3, pp. 203–207, 2003.

[90] C. M. Gomes, F. D. S. Damasco, O. O. de Morais, C. D. R. de Paula, and R. N. R. Sampaio, “Recurrent cutaneous leishmaniasis,” *Anais Brasileiros de Dermatologia*, vol. 88, no. 3, pp. 462–464, 2013.